Blue Owl Capital Holdings LP Invests $8.48 Million in Artiva Biotherapeutics, Inc. $ARTV

Blue Owl Capital Holdings LP bought a new position in Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 874,542 shares of the company’s stock, valued at approximately $8,483,000. Artiva Biotherapeutics comprises about 1.3% of Blue Owl Capital Holdings LP’s investment portfolio, making the stock its 16th biggest position.

A number of other hedge funds also recently bought and sold shares of the business. Citadel Advisors LLC lifted its holdings in Artiva Biotherapeutics by 419.3% in the 3rd quarter. Citadel Advisors LLC now owns 798,397 shares of the company’s stock worth $2,291,000 after buying an additional 644,658 shares during the period. BlackRock Inc. bought a new position in shares of Artiva Biotherapeutics during the second quarter valued at approximately $6,739,000. BNP Paribas Financial Markets lifted its stake in Artiva Biotherapeutics by 14,463.5% in the third quarter. BNP Paribas Financial Markets now owns 118,547 shares of the company’s stock worth $340,000 after acquiring an additional 117,733 shares during the period. Renaissance Technologies LLC lifted its stake in Artiva Biotherapeutics by 46.8% in the fourth quarter. Renaissance Technologies LLC now owns 116,200 shares of the company’s stock worth $498,000 after acquiring an additional 37,053 shares during the period. Finally, Marshall Wace LLP bought a new stake in Artiva Biotherapeutics in the fourth quarter valued at $341,000.

Artiva Biotherapeutics Stock Down 4.8%

Shares of ARTV stock opened at $11.14 on Friday. The stock has a market cap of $544.63 million, a price-to-earnings ratio of -3.38 and a beta of 2.16. The business’s fifty day moving average is $10.12 and its 200 day moving average is $8.21. Artiva Biotherapeutics, Inc. has a twelve month low of $2.22 and a twelve month high of $14.53.

Artiva Biotherapeutics (NASDAQ:ARTV) last announced its earnings results on Thursday, August 6th. The company reported ($0.63) EPS for the quarter, meeting analysts’ consensus estimates of ($0.63). Equities research analysts expect that Artiva Biotherapeutics, Inc. will post -2.62 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on ARTV shares. Wall Street Zen raised shares of Artiva Biotherapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, August 8th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Artiva Biotherapeutics in a research note on Tuesday, May 26th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Artiva Biotherapeutics in a research report on Tuesday, July 21st. Needham & Company LLC reissued a “buy” rating and issued a $41.00 price target on shares of Artiva Biotherapeutics in a research note on Monday, June 8th. Finally, Wedbush raised their price objective on shares of Artiva Biotherapeutics from $23.00 to $40.00 and gave the stock an “outperform” rating in a report on Monday, May 11th. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $39.00.

Insider Buying and Selling

In other Artiva Biotherapeutics news, Director Ra Capital Management, L.P. acquired 24,944 shares of the business’s stock in a transaction on Friday, July 31st. The shares were acquired at an average price of $9.93 per share, for a total transaction of $247,693.92. Following the completion of the acquisition, the director owned 17,329,570 shares in the company, valued at $172,082,630.10. This trade represents a 0.14% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders have bought a total of 1,965,251 shares of company stock worth $16,188,035 over the last 90 days. Insiders own 1.80% of the company’s stock.

Artiva Biotherapeutics Company Profile

Artiva Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of allogeneic “off-the-shelf” cell therapies for cancer. The company’s proprietary platform leverages natural killer (NK) cells engineered to express chimeric antigen receptors (CARs) or other targeting modalities, with the goal of delivering potent anti-tumor activity while minimizing the safety and supply limitations associated with patient-derived (autologous) approaches.

Artiva’s pipeline includes multiple lead product candidates designed to address both hematologic malignancies and solid tumors.